Potential clinical treatment for Ebola pandemic

Science China Life Sciences

Volumn 57, Issue 10, 2014, Pages 982-984

  Zhong, Ying ^a   Xu, Jun ^b   Li, TaiSheng ^b   Yu, XueZhong ^b   Sheng, MiaoMiao ^c  

^a TSINGHUA UNIVERSITY   (China)

^b PEKING UNION MEDICAL COLLEGE HOSPITAL   (China)

^c KUNMING UNIVERSITY OF SCIENCE AND TECHNOLOGY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

RIBAVIRIN;

AFRICA; ANIMAL; EPIDEMIC; HEMORRHAGIC FEVER, EBOLA; HUMAN; MOUSE; PANDEMIC; VIROLOGY;

AFRICA, WESTERN; ANIMALS; DISEASE OUTBREAKS; HEMORRHAGIC FEVER, EBOLA; HUMANS; MICE; PANDEMICS; RIBAVIRIN;

EID: 84922002808     PISSN: 16747305     EISSN: 18691889     Source Type: Journal    
DOI: 10.1007/s11427-014-4756-5     Document Type: Article

References (15)

1. Geisbert TW, Hensley LE, Jahrling PB, Larsen T, Geisbert JB, Paragas J, Young HA, Fredeking TM, Rote WE, Vlasuk GP. Treatment of Ebola virus infection with a recombinant inhibitor of factor VIIa/tissue factor: a study in rhesus monkeys. Lancet, 2003, 362: 1953–1958
2. Oestereich L, Ludtke A, Wurr S, Rieger T, Munoz-Fontela C, Gunther S. Successful treatment of advanced Ebola virus infection with T-705 (favipiravir) in a small animal model. Antiviral Res, 2014, 105: 17–21
3. Warren TK, Wells J, Panchal RG, Stuthman KS, Garza NL, Van Tongeren SA, Dong L, Retterer CJ, Eaton BP, Pegoraro G, Honnold S, Bantia S, Kotian P, Chen X, Taubenheim BR, Welch LS, Minning DM, Babu YS, Sheridan WP, Bavari S. Protection against filovirus diseases by a novel broad-spectrum nucleoside analogue BCX4430. Nature, 2014, 508: 402–405
4. Olinger GG, Jr., Pettitt J, Kim D, Working C, Bohorov O, Bratcher B, Hiatt E, Hume SD, Johnson AK, Morton J, Pauly M, Whaley KJ, Lear CM, Biggins JE, Scully C, Hensley L, Zeitlin L. Delayed treatment of Ebola virus infection with plant-derived monoclonal antibodies provides protection in rhesus macaques. Proc Natl Acad Sci USA, 2012, 109: 18030–18035
5. Warren TK, Warfield KL, Wells J, Swenson DL, Donner KS, Van Tongeren SA, Garza NL, Dong L, Mourich DV, Crumley S, Nichols DK, Iversen PL, Bavari S. Advanced antisense therapies for postexposure protection against lethal filovirus infections. Nat Med, 2010, 16: 991–994
6. Uebelhoer LS, Albarino CG, McMullan LK, Chakrabarti AK, Vincent JP, Nichol ST, Towner JS. High-throughput, luciferase-based reverse genetics systems for identifying inhibitors of Marburg and Ebola viruses. Antiviral Res, 2014, 106: 86–94
7. Johansen LM, Brannan JM, Delos SE, Shoemaker CJ, Stossel A, Lear C, Hoffstrom BG, Dewald LE, Schornberg KL, Scully C, Lehar J, Hensley LE, White JM, Olinger GG. FDA-approved selective estrogen receptor modulators inhibit Ebola virus infection. Sci Translat Med, 2013, 5: 190ra179
8. Gehring G, Rohrmann K, Atenchong N, Mittler E, Becker S, Dahlmann F, Pohlmann S, Vondran FW, David S, Manns MP, Ciesek S, von Hahn T. The clinically approved drugs amiodarone, dronedarone and verapamil inhibit filovirus cell entry. J Antimicrob Chemother, 2014, 69: 2123–2131
9. Dokuzoguz B, Celikbas AK, Gok SE, Baykam N, Eroglu MN, Ergonul O. Severity scoring index for crimean-congo hemorrhagic fever and the impact of ribavirin and corticosteroids on fatality. Clin Infect Dis, 2013, 57: 1270–1274
10. Lee W, Ku SK, Bae JS. Barrier protective effects of rutin in LPS-induced inflammation in vitro and in vivo. Food Chem Toxicol, 2012, 50: 3048–3055
11. Whitehouse CA. Crimean-Congo hemorrhagic fever. Antiviral Res, 2004, 64: 145–160
12. May JM, Harrison FE. Role of vitamin C in the function of the vascular endothelium. Antioxid Redox Signal, 2013, 19: 2068–2083
13. Sharifi-Mood B, Alavi-Naini R, Metanat M, Mohammadi M, Shakeri A, Amjadi A. Efficacy of high-dose methylprednisolone in patients with Crimean-Congo haemorrhagic fever and severe thrombocytopenia. Trop Doct, 2013, 43: 49–53
14. Patel JM, Snaith C, Thickett DR, Linhartova L, Melody T, Hawkey P, Barnett AH, Jones A, Hong T, Cooke MW, Perkins GD, Gao F. Randomized double-blind placebo-controlled trial of 40 mg/day of atorvastatin in reducing the severity of sepsis in ward patients (asepsis trial). Crit Care, 2012, 16: R231
15. Undas A, Brummel-Ziedins KE, Mann KG. Anticoagulant effects of statins and their clinical implications. Thromb Haemost, 2014, 111: 392–400